veterans
decreased
renal
function
shown
higher
risk
adverse
cardiovascular
events
moderately
elevated
triglyceride
tg
levels
despite
dublin
ireland
bridgewater
globe
newswire
amarin
corporation
plc
nasdaq
amrn
today
announced
presentation
evidence
data
american
society
nephrology
asn
kidney
week
held
virtually
october
october
adding
growing
body
knowledge
association
elevated
triglyceride
tg
levels
increased
cardiovascular
cv
risk
independent
cholesterol
management
new
analyses
conducted
department
veterans
affairs
supported
amarin
presented
poster
presentation
sarah
leatherman
department
veterans
affairs
retrospective
analysis
used
data
veterans
affairs
corporate
data
warehouse
analysis
consisted
patients
veterans
treated
triglyceride
management
baseline
lipoprotein
ldl
levels
mg
dl
decreased
renal
function
egfr
ml
min
patients
elevated
tg
levels
mg
dl
cohort
patients
compared
patients
similarly
decreased
renal
function
normal
baseline
tg
levels
mg
dl
veterans
within
cohort
elevated
tg
levels
experienced
higher
rates
composite
individual
major
adverse
events
cardiovascular
events
myocardial
infarctions
stroke
unstable
angina
coronary
revascularization
control
cohort
overall
crude
adjusted
cardiovascular
event
rate
ratios
ci
ci
respectively
analysis
supports
hypothesis
elevated
tg
levels
independent
identifier
cardiovascular
risk
analysis
assess
extent
lowering
tg
levels
results
lower
cv
risk
department
veterans
affairs
analysis
presented
asn
kidney
week
shows
veterans
decreased
renal
function
elevated
triglycerides
increased
risk
major
adverse
cardiovascular
event
supporting
need
look
elevated
triglycerides
independent
marker
cardiovascular
risk
even
already
patients
like
analyzed
study
said
craig
granowitz
amarin
senior
vice
president
chief
medical
officer
results
add
support
recent
epidemiological
genetic
linkage
studies
shown
elevated
baseline
tg
levels
could
potentially
factor
increased
incidence
cardiovascular
notable
presentations
asn
kidney
week
increased
residual
cardiovascular
risk
us
veterans
moderately
elevated
baseline
triglycerides
ldl
cholesterol
levels
statins
decreased
renal
function
presented
behalf
authors
sarah
leatherman
available
october
benefits
icosapent
ethyl
across
range
baseline
renal
function
patients
established
cardiovascular
disease
diabetes
results
renal
presented
behalf
authors
arjun
majithia
october
pm
edt
additional
information
asn
kidney
week
found
amarin
amarin
corporation
plc
rapidly
growing
innovative
pharmaceutical
company
focused
developing
commercializing
therapeutics
improve
cardiovascular
health
amarin
lead
product
icosapent
ethyl
available
prescription
united
states
canada
lebanon
united
arab
emirates
vascepa
yet
approved
available
countries
amarin
together
commercial
partners
select
geographies
pursuing
additional
regulatory
approvals
vascepa
china
europe
middle
east
information
amarin
visit
cardiovascular
risk
number
deaths
united
states
attributed
cardiovascular
disease
continues
rise
new
recurrent
heart
attacks
per
year
approximately
every
seconds
united
states
stroke
rates
per
year
approximately
every
seconds
accounting
every
deaths
cardiovascular
disease
results
deaths
per
year
united
aggregate
million
major
adverse
cardiovascular
events
per
year
cardiovascular
disease
average
one
every
seconds
united
states
alone
controlling
bad
cholesterol
also
known
one
way
reduce
patient
risk
cardiovascular
events
heart
attack
stroke
death
however
even
achievement
target
levels
millions
patients
still
significant
persistent
risk
cardiovascular
events
especially
patients
elevated
triglycerides
statin
therapy
shown
control
thereby
reducing
risk
cardiovascular
events
significant
cardiovascular
risk
remains
statin
therapy
people
elevated
triglycerides
cardiovascular
events
compared
people
normal
range
triglycerides
taking
global
cardiovascular
outcomes
study
designed
evaluate
effect
vascepa
adult
patients
controlled
mg
dl
median
baseline
mg
dl
statin
therapy
various
cardiovascular
risk
factors
including
persistent
elevated
triglycerides
mg
dl
median
baseline
mg
dl
either
established
cardiovascular
disease
secondary
prevention
cohort
diabetes
mellitus
least
one
cardiovascular
risk
factor
primary
prevention
cohort
conducted
seven
years
completed
followed
patients
clinical
sites
countries
largest
number
sites
located
within
united
states
conducted
based
special
protocol
assessment
agreement
fda
design
study
published
march
clinical
primary
results
published
new
england
journal
medicine
november
total
events
results
published
journal
american
college
cardiology
march
publications
found
r
section
company
website
icosapent
ethyl
capsules
vascepa
icosapent
ethyl
capsules
prescription
treatment
approved
fda
comprised
solely
active
ingredient
icosapent
ethyl
ipe
unique
form
eicosapentaenoic
acid
vascepa
initially
launched
united
states
based
drug
initial
fda
approved
indication
use
adjunct
therapy
diet
reduce
triglyceride
levels
adult
patients
severe
mg
dl
hypertriglyceridemia
since
launch
vascepa
prescribed
eight
million
times
vascepa
covered
major
medical
insurance
plans
new
cardiovascular
risk
indication
vascepa
approved
fda
december
indications
limitation
use
vascepa
indicated
adjunct
maximally
tolerated
statin
therapy
reduce
risk
myocardial
infarction
stroke
coronary
revascularization
unstable
angina
requiring
hospitalization
adult
patients
elevated
triglyceride
tg
levels
mg
dl
established
cardiovascular
disease
diabetes
mellitus
two
additional
risk
factors
cardiovascular
disease
adjunct
diet
reduce
tg
levels
adult
patients
severe
mg
dl
hypertriglyceridemia
effect
vascepa
risk
pancreatitis
patients
severe
hypertriglyceridemia
determined
important
safety
information
vascepa
contraindicated
patients
known
hypersensitivity
anaphylactic
reaction
vascepa
components
vascepa
associated
increased
risk
vs
atrial
fibrillation
atrial
flutter
requiring
hospitalization
trial
incidence
atrial
fibrillation
greater
patients
previous
history
atrial
fibrillation
atrial
flutter
known
whether
patients
allergies
fish
shellfish
increased
risk
allergic
reaction
vascepa
patients
allergies
discontinue
vascepa
reactions
occur
vascepa
associated
increased
risk
vs
bleeding
trial
incidence
bleeding
greater
patients
receiving
concomitant
antithrombotic
medications
aspirin
clopidogrel
warfarin
common
adverse
reactions
cardiovascular
outcomes
trial
incidence
frequent
placebo
musculoskeletal
pain
vs
peripheral
edema
vs
constipation
vs
gout
vs
atrial
fibrillation
vs
common
adverse
reactions
hypertriglyceridemia
trials
incidence
frequent
placebo
arthralgia
vs
oropharyngeal
pain
vs
frequent
placebo
arthralgia
vs
oropharyngeal
pain
vs
adverse
events
may
reported
calling
fda
patients
receiving
vascepa
concomitant
anticoagulants
agents
monitored
bleeding
key
clinical
effects
vascepa
major
adverse
cardiovascular
events
included
clinical
studies
section
prescribing
information
vascepa
set
forth
effect
vascepa
time
first
occurrence
cardiovascular
events
patients
elevated
triglyceride
levels
risk
factors
cardiovascular
disease
vascepa
placebo
vascepa
vs
placebo
n
n
incidence
rate
per
patient
years
n
n
incidence
rate
per
patient
years
hazard
ratio
ci
primary
composite
endpoint
cardiovascular
death
myocardial
infarction
stroke
coronary
revascularization
hospitalization
unstable
angina
mace
key
secondary
composite
endpoint
cardiovascular
death
myocardial
infarction
stroke
mace
secondary
endpoints
fatal
myocardial
infarction
emergent
urgent
coronary
revascularization
cardiovascular
death
hospitalization
unstable
angina
fatal
stroke
includes
adjudicated
cardiovascular
deaths
deaths
undetermined
causality
determined
caused
myocardial
ischemia
invasive
testing
requiring
emergent
hospitalization
full
vascepa
prescribing
information
found
statements
press
release
contains
statements
including
statements
regarding
potential
impact
vascepa
various
clinical
uses
statements
promises
guarantees
involve
substantial
risks
uncertainties
among
factors
could
cause
actual
results
differ
materially
described
projected
herein
include
following
uncertainties
associated
generally
research
development
clinical
trials
clinical
evaluations
failing
confirm
earlier
findings
list
description
risks
uncertainties
risks
associated
investment
amarin
found
amarin
filings
securities
exchange
commission
including
recent
quarterly
report
form
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
hereof
amarin
undertakes
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
amarin
statements
reflect
potential
impact
significant
transactions
company
may
enter
mergers
acquisitions
dispositions
joint
ventures
material
agreements
amarin
may
enter
amend
terminate
availability
information
amarin
investors
others
note
amarin
communicates
investors
public
using
company
website
investor
relations
website
including
limited
investor
presentations
investor
faqs
securities
exchange
commission
filings
press
releases
public
conference
calls
webcasts
information
amarin
posts
channels
websites
could
deemed
material
information
result
amarin
encourages
investors
media
others
interested
amarin
review
information
posted
channels
including
investor
relations
website
regular
basis
list
channels
may
updated
time
time
amarin
investor
relations
website
may
include
social
media
channels
contents
amarin
website
channels
website
may
accessed
website
channels
shall
deemed
incorporated
reference
filing
securities
act
amarin
contact
information
investor
inquiries
elisabeth
schwartz
investor
relations
amarin
corporation
plc
ir
investor
inquiries
lee
stern
solebury
trout
lstern
media
inquiries
alina
kolomeyer
communications
amarin
corporation
plc
pr
media
inquiries
budoff
triglycerides
lipoproteins
causal
pathway
cardiovascular
disease
j
cardiol
toth
pp
granowitz
c
hull
et
al
high
triglycerides
associated
increased
cardiovascular
events
medical
costs
resource
use
administrative
claims
analysis
patients
high
residual
cardiovascular
risk
j
heart
assoc
nordestgaard
bg
lipoproteins
atherosclerotic
cardiovascular
disease
new
insights
epidemiology
genetics
biology
circ
res
american
heart
association
heart
disease
stroke
update
report
american
heart
association
circulation
ganda
op
bhatt
dl
mason
rp
et
al
unmet
need
adjunctive
dyslipidemia
therapy
hypertriglyceridemia
management
j
coll
cardiol
budoff
triglycerides
lipoproteins
causal
pathway
cardiovascular
disease
j
cardiol
toth
pp
granowitz
c
hull
et
al
high
triglycerides
associated
increased
cardiovascular
events
medical
costs
resource
use
administrative
claims
analysis
patients
high
residual
cardiovascular
risk
j
heart
assoc
nordestgaard
bg
lipoproteins
atherosclerotic
cardiovascular
disease
new
insights
epidemiology
genetics
biology
circ
res
bhatt
dl
steg
pg
brinton
e
et
behalf
investigators
rationale
design
reduction
cardiovascular
events
icosapent
trial
clin
cardiol
bhatt
dl
steg
pg
miller
et
behalf
investigators
cardiovascular
risk
reduction
icosapent
ethyl
hypertriglyceridemia
n
engl
j
med
bhatt
dl
steg
pg
miller
et
behalf
investigators
reduction
first
total
ischemic
events
icosapent
ethyl
across
baseline
triglyceride
tertiles
j
coll
cardiol
